Regadenoson: a new myocardial stress agent

J Am Coll Cardiol. 2009 Sep 22;54(13):1123-30. doi: 10.1016/j.jacc.2009.04.089.


Vasodilator stress myocardial perfusion imaging (MPI) accounts for up to 50% of all stress MPI studies performed in the U.S. In 2008, the Food and Drug Administration approved regadenoson for stress testing in conjunction with MPI. Regadenoson, unlike adenosine, is a selective A(2A) agonist that is given as an intravenous bolus at a fixed dose, with less undesirable side effects including atrioventricular block and bronchospasm. Unlike adenosine, regadenoson could be used in patients with mild-to-moderate reactive airway disease. This review will summarize the pre-clinical and clinical data on regadenoson, as they specifically relate to its use as a vasodilator stress agent, currently the only approved selective A(2A) agonist.

Publication types

  • Review

MeSH terms

  • Blood Pressure / drug effects
  • Coronary Artery Disease / diagnosis*
  • Coronary Artery Disease / physiopathology
  • Exercise Test
  • Heart Rate / drug effects
  • Humans
  • Myocardial Perfusion Imaging*
  • Purines / adverse effects
  • Purines / chemistry
  • Purines / pharmacology*
  • Pyrazoles / adverse effects
  • Pyrazoles / chemistry
  • Pyrazoles / pharmacology*
  • Vasodilator Agents / adverse effects
  • Vasodilator Agents / chemistry
  • Vasodilator Agents / pharmacology*


  • Purines
  • Pyrazoles
  • Vasodilator Agents
  • regadenoson